Coenzyme Q0
Based on 2 publication(s) in Google Scholar
Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling.
For research use only. We do not sell to patients.
- Purity: 99.79%
- CAS No.: 605-94-7
- Formula: C9H10O4
- Molecular Weight:182.18
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Coenzyme Q0
MoreAll EGFR Isoforms
MoreAll Caspase Isoforms
More
Biological Activity
Coenzyme Q0 (0-40 μM; 24 h) and inhibits viability and growth of human ovarian carcinoma cells[1].
Coenzyme Q0 (CoQ0) (0-30 μM; 24 h; SKOV-3 cells) has anti-proliferative activity through induction of G2/M cell-cycle arrest and reduction of cell-cycle regulatory proteins[1].
Coenzyme Q0 (CoQ0) (0-30 μM; 0-30 min; SKOV-3 cells) increases intracellular ROS levels to promote SKOV-3 cell death[1].
Coenzyme Q0 (CoQ0) (0-30 μM; 24 h; SKOV-3 cells) induces autophagy by increase accumulation of LC3-II, GFP-LC3 puncta, AVOs formation and Beclin-1/Bcl-2 dysregulation[1].
Coenzyme Q0 (CoQ0) (0-30 μM; 24 h; SKOV-3 cells) induces apoptosis by mitochondrial (caspase-3, PARP and Bax/Bcl-2 dysregulation) and ER stress (caspase-12 and Hsp70) signals[1].
Coenzyme Q0 (CoQ0) (30 μM; 24 h; SKOV-3 cells) suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms[1].
Coenzyme Q0 (CoQ0) (0-10 μM; 0.5-18 h; RAW264.7 cells) regulates NFκB/AP-1 activation and enhances Nrf2 stabilization[2].
Coenzyme Q0 (CoQ0) (5 μM; 0-12 h; EA.hy 926 cells) has anti-angiogenic activity in EA.hy 926 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SKOV-3, A2780 and A2870/CP70 cells
-
Concentration:0, 10, 20, 30 and 40 µM
-
Incubation Time:24 hours
-
Result:Decreased viability with the IC50 values of 26.6 µM, 27.3 µM and 28.4 µM for SKOV-3, A2780 and A2870/CP70 cells, respectively.
-
Cell Line:SKOV-3, A2780 and A2870/CP70 cells
-
Concentration:0, 10, 20 and 30 µM
-
Incubation Time:24 hours
-
Result:Arrested cell cycle at G2/M phase and reduced cell-cycle proteins in SKOV-3 cells.
-
Cell Line:SKOV-3, A2780 and A2870/CP70 cells
-
Concentration:0, 5, 15 and 30 µM
-
Incubation Time:24 hours
-
Result:Promoted the conversion of LC3–1 to LC3-II and increased the LC3-II accumulation. Increased Bax/Bcl-2 ratio in a dose-dependent manner.
-
Cell Line:SKOV-3 cells
-
Concentration:0, 10, 20 and 30 µM
-
Incubation Time:24 hours
-
Result:Had the percentage of early apoptotic cells are 25.1%, 34% and 36% for 10, 20 and 30 µM, respectively.
-
Cell Line:SKOV-3 cells
-
Concentration:0, 5, 15 and 30 µM
-
Incubation Time:24 hours
-
Result:Activated of caspase-3 and cleavaged of PARP. Increased the expressions of caspase-12, HSP-70 and Bax in a dose-dependent manner, decreased the expressions of Bcl-2.
-
Cell Line:SKOV-3 cells
-
Concentration:30 µM
-
Incubation Time:24 hours
-
Result:Decreased the phosphorylated HER-2 (Y1221) levels, p-AKT (Ser473) and p-mTOR (S2448) levels.
-
Cell Line:RAW264.7 cells
-
Concentration:0, 2.5, 5 and 10 µM
-
Incubation Time:0.5-18 hours
-
Result:Inhibited iNOS/COX-2 protein expressions with reductions of NO, PGE2, TNF-α and IL-1β secretions.
-
Cell Line:EA.hy 926 cells
-
Concentration:5 µM
-
Incubation Time:0, 1, 3, 6 and 12 hours
-
Result:Increased expressions of heme oxygenase-1 (HO-1) and γ-glutamylcysteine synthetase (γ-GCLC), inhibits protein expressions of matrix metalloproteinase-9 (MMP-9), reduces TNF-α-induced nuclear translocation and transcriptional activation of nuclear factor-κB (NF-κB).
Coenzyme Q0(CoQ0) (5 mg/kg; p.o.; for 4 h) has anti-inflammatory activities through Nrf2 activation and NFκB inhibition in liver and spleen of LPS-treated mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SKOV-3 xenografted nude mice[1]
-
Dosage:1.5 and 2.5 mg/kg
-
Administration:Intraperitoneal injection; Once every four days, for 52 days
-
Result:Inhibited the tumor growth at 1.5 and 2.5 mg/kg.
-
Animal Model:LPS-treated female FVB mice[2]
-
Dosage:5 mg/kg
-
Administration:Oral administration; for 4 hours
-
Result:Down-regulates inflammatory genes in liver and spleen tissues of LPS injected mice.
Chemical Information
-
CAS No. 605-94-7
-
Appearance Solid
-
Molecular Weight 182.18
-
Formula C9H10O4
-
Color Brown to red
-
SMILES
O=C1C(OC)=C(OC)C(C(C)=C1)=O
-
Synonyms
CoQ0
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Emerg Microbes Infect
First report of Candida auris in Guangdong, China: clinical and microbiological characteristics of 7 episodes of candidemia. [Abstract]2024 Dec;13(1):2300525. PMID: 38164742 -
FASEB J
Amphiregulin improves ventricular remodeling after myocardial infarction by modulating autophagy and apoptosis. [Abstract]2024 Feb 29;38(4):e23488. PMID: 38358359
Solvent & Solubility
DMSO : 50 mg/mL (274.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (9.17 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (9.17 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61. [Content Brief]
[2]. Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61. [Content Brief]
[3]. Yang HL, et, al. Anti-angiogenic properties of coenzyme Q0 through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling in TNF-α-activated human endothelial cells. Biochem Pharmacol. 2015 Nov 1;98(1):144-56. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.4891 mL | 27.4454 mL | 54.8908 mL | 137.2269 mL |
| 5 mM | 1.0978 mL | 5.4891 mL | 10.9782 mL | 27.4454 mL | |
| 10 mM | 0.5489 mL | 2.7445 mL | 5.4891 mL | 13.7227 mL | |
| 15 mM | 0.3659 mL | 1.8297 mL | 3.6594 mL | 9.1485 mL | |
| 20 mM | 0.2745 mL | 1.3723 mL | 2.7445 mL | 6.8613 mL | |
| 25 mM | 0.2196 mL | 1.0978 mL | 2.1956 mL | 5.4891 mL | |
| 30 mM | 0.1830 mL | 0.9148 mL | 1.8297 mL | 4.5742 mL | |
| 40 mM | 0.1372 mL | 0.6861 mL | 1.3723 mL | 3.4307 mL | |
| 50 mM | 0.1098 mL | 0.5489 mL | 1.0978 mL | 2.7445 mL | |
| 60 mM | 0.0915 mL | 0.4574 mL | 0.9148 mL | 2.2871 mL | |
| 80 mM | 0.0686 mL | 0.3431 mL | 0.6861 mL | 1.7153 mL | |
| 100 mM | 0.0549 mL | 0.2745 mL | 0.5489 mL | 1.3723 mL |
Coenzyme Q0 Related Classifications
HY-W016412 Related Classifications
Powered by Bioz
- Coenzyme Q0
- 605-94-7
- CoQ0
- Coenzyme Q 0
- Coenzyme Q-0
- CoQ 0
- CoQ-0
- Apoptosis
- Autophagy
- EGFR
- Akt
- mTOR
- Caspase
- Bcl-2 Family
- Reactive Oxygen Species (ROS)
- PARP
- COX
- NO Synthase
- TNF Receptor
- Interleukin Related
- MMP
- NF-κB
- anticancer
- anti-angiogenic
- anti-inflammation
- HO-1
- ubiquinone compound
- Antrodia cinnamomea
- Inhibitor
- inhibitor
- inhibit